Shire entered into a US$150 M worth deal with Noven. The deal granted Shire, the exclusive global rights to Noven’s MethyPatch®, a once daily methylphenidate transdermal system for the treatment of attention deficit hyperactivity disorder (ADHD). This article considers the potential impact of the deal on both Shire and Noven with respect to the companies’ existing therapeutic focuses, their business strategies and the growing ADHD market.